

Agenda

Friday 3rd May 2019, 13:00 - 14:00
Vienna Hall, Ground Floor, Maritim Hotel Berlin
Chair: Dr. Fabrice André

ESMO Breast Cancer 2019
Daiichi Sankyo Satellite Symposium

Targeting HER Driven Breast Cancer Emerging And Future Options

Faculty

Dr. **Fabrice André**, MD, PhD

Institut Gustave Roussy, Villejuif, France

Dr. **Hope S. Rugo**, MD

USCF, San Francisco, USA

Dr. **Javier Cortés**, MD, PhD

IOB Institute of Oncology, Madrid & Barcelona, Spain

13:00 - 13:05	Welcome & Introduction	Fabrice André
13:05 - 13:20	Current progress in HER2 positive metastatic breast cancer	Hope S. Rugo
13:20 - 13:35	Evolution of HER2 targeted therapies: The role of antibody drug conjugates	Fabrice André
13:35 - 13:50	The emerging treatment paradigm for HER driven breast cancer	Javier Cortés
13:50 - 14:00	Q & A with Speaker Panel	All Faculty Members

Programme Overview

In metastatic breast cancer (mBC) driven by HER2, treatment targeting HER2 has significantly improved outcomes. In the past 30 years, successive generations of monoclonal antibodies (mAb) and antibody drug conjugates (ADC) targeting HER2 have been developed. Recent progression in understanding of the mechanisms of resistance to existing therapies has also helped to direct clinical investigation into pathways and targets to overcome treatment barriers for those with advanced disease. Nevertheless, for patients with mBC driven by HER2, there are ongoing unmet needs for greater efficacy and improved safety.

In order to help busy clinicians and oncology healthcare professionals understand the emerging data which will aid future management of their patients, this symposium will review the latest thinking for breast cancer driven by HER2 and its implications for clinical practice. This program will also include interactive questions for the audience and a question-and-answer session with the faculty.



Daiichi-Sankyo
cancerenterprise

Care. Compassion. Science.
It's Our Obligation.